CoChat

Adherence is associated with a favorable outcome after lung transplantation

Open access
Bertram, Anna, Fuge, Jan, Suhling, Hendrik, Tudorache, Igor, Haverich, Axel, Welte, Tobias, Gottlieb, Jens · 2019 · PLoS ONE

The DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index; 10 of the 52 sources its claims cite were checked for support.

Abstract

Patients with good adherence within the first three years showed better 5-year allograft and patient survival and lower prevalence of chronic allograft dysfunction after 5 years compared to patients with suboptimal adherence.

Overview

CoChat Summary

TL;DR

In this single-center retrospective cohort of 427 adult lung transplant recipients, a multidimensional adherence score assessed during routine follow-up was associated with better 5-year allograft and patient survival. Patients with good adherence in the first 3 years had higher 5-year allograft survival (74% vs. 60%), higher patient survival (79% vs. 64%), and lower CLAD prevalence (33% vs. 45%).

Key findings

  • Median adherence in the first 3 years after lung transplantation was 86% (IQR 79–90%) across 6,623 scored visits.
  • Using the 86% median cutoff, patients with good adherence had better 5-year allograft survival (74% vs. 60%, p = 0.003), patient survival (79% vs. 64%, p < 0.001), and lower CLAD prevalence (33% vs. 45%, p = 0.011).
  • Patients with suboptimal adherence had more and longer hospitalizations; quality of life tended to improve over time in the good-adherence group and decline in the low-adherence group.
  • In multivariate logistic regression, only the subscore “home spirometry” showed a significant association with patient survival, with an odds ratio of 4.2 (p = 0.008) for negative outcome.

Methods

  • Design: Single-center retrospective cohort study at Hannover Medical School; adherence was assessed prospectively at every outpatient visit using a five-item, healthcare-worker-rated Likert score (0–100%).
  • Sample/data: Included 427 adult patients with first lung transplantation between January 1, 2010 and December 31, 2013 who entered outpatient follow-up; median follow-up was 5.9 years (IQR 4.1–7.3).
  • Analysis: ROC curves, median-based cutoff selection, chi-square/Fisher tests, Mann-Whitney U/t tests, Kaplan-Meier survival analyses with log-rank tests, and stratified analyses by diagnosis; multivariate logistic regression was used for subscores.

Limitations

  • The paper states it was a single-center retrospective study, and that interventions to improve adherence were performed and may have interfered.
  • The authors note that not all factors lowering the score reflected non-adherence; drug interactions, malabsorption, medical complications, or wasting/underweight could also affect scores.
  • The adherence score was not validated, and inter-observer variability was not tested; the text says this was partly because the score was completed by coordinators, checked by physicians, and discussed in team meetings.
  • Evident from the text: the study is observational, so the reported associations cannot establish causality.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0226167

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Adherence score comparison over time. Median combined adherence scores with IQR and outliers within the first three years after LTx.
Fig 1 Adherence score comparison over time. Median combined adherence scores with IQR and outliers within the first three years after LTx.CC BY · PubMed Central
Fig 2 Good vs. suboptimal adherers over time. Histograms with the relative frequency (density) of combined adherence scores (x axis) for suboptimal vs. good adherers within the first three years after LTx. Patients with suboptimal adherence, i.e., below the median of 86% (upper panel), tended to a decline in their scores from year 1 to year 3. Patients with good adherence (lower panel) tended to keep their level.
Fig 2 Good vs. suboptimal adherers over time. Histograms with the relative frequency (density) of combined adherence scores (x axis) for suboptimal vs. good adherers within the first three years after LTx. Patients with suboptimal adherence, i.e., below the median of 86% (upper panel), tended to a decline in their scores from year 1 to year 3. Patients with good adherence (lower panel) tended to keep their level.CC BY · PubMed Central
Fig 3 Survival estimates comparisons by adherence score cut-off. Kaplan-Meier estimates for 5 year (A) patient survival, (B) allograft survival, and (C) CLAD-free survival for patients with a 1–3 years good (dashed line) or suboptimal adherence (continuous line).
Fig 3 Survival estimates comparisons by adherence score cut-off. Kaplan-Meier estimates for 5 year (A) patient survival, (B) allograft survival, and (C) CLAD-free survival for patients with a 1–3 years good (dashed line) or suboptimal adherence (continuous line).CC BY · PubMed Central
Fig 4 Adherence score and subscore comparisons by diagnosis group. Median combined adherence score and median subscores 1 (health perception), 2 (home monitoring), 3 (contact), 4 (nutrition, exercise), and 5 (trough levels) by diagnosis group. Medians are shown with IQR and outliers.
Fig 4 Adherence score and subscore comparisons by diagnosis group. Median combined adherence score and median subscores 1 (health perception), 2 (home monitoring), 3 (contact), 4 (nutrition, exercise), and 5 (trough levels) by diagnosis group. Medians are shown with IQR and outliers.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 2 Not valid · 24 Not checked · 51 Own results and interpretations

14 more claims

Create a free account to see all 85 claims and to verify the 10 references still open.

See all claims — free account
  • Probably not a substantial claim. 52
  • It may state two separate claims as one. 30

Create a free account to see these claims.

Citations

Cites

Show all 53 references

Cited by

Metadata

Authors
Bertram, A., Fuge, J., Suhling, H., Tudorache, I., Haverich, A., Welte, T., & Gottlieb, J.
Affiliations
Medizinische Hochschule Hannover (DE)
Corresponding author
Bertram, Anna
Venue
PLoS ONE
Published
2019-12-17
Volume
14
Issue
12
Pages
e0226167
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2996507705
Cited by
34
References
56
Citations by year
2026: 7 · 2025: 5 · 2024: 1 · 2023: 5 · 2022: 7 · 2021: 3 · 2020: 4 · 2019: 1
FWCI
3.17
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Keywords
medication adherence, lung transplantation, allograft survival, chronic lung allograft dysfunction, patient survival, trough level monitoring, home spirometry, quality of life
MeSH terms
Adult, Child, Female, Humans, Male, Middle Aged, Patient Compliance, Quality of Life, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.